Navigation Links
Vaccinex Antibody Licensed to GlaxoSmithKline
Date:2/15/2008

ROCHESTER, N.Y., Feb. 15 /PRNewswire/ -- EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

"We are pleased that our collaboration in the discovery and co-development of OP-R003 has attracted such a world-class partner as GSK. Together with previously announced antibody partnerships with Biocon, Ltd. and Teva Pharmaceutical, this transaction further validates the quality of human antibodies selected with Vaccinex's ActivMAb(R) antibody discovery technology," remarked Dr. Maurice Zauderer, Vaccinex's President and CEO.

Commenting on the acquisition, Brian McVeigh, GSK's Worldwide Business Development Director of M&A Strategy and Transactions, said, "Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs."

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other system
'/>"/>

SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Human Genome Sciences and Xencor Announce Antibody Collaboration
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Roche Files IND for Second Genmab Antibody
7. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
8. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
9. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... A mechanised blue dye test alter...ckaging quality assurance one step closer for phar... leak testing machine developed by Sepha for u...alled in several local and global pharma-companies...s quality assurance and productivity improvements ...
(Date:11/25/2009)... , BOSTON, Nov. 25 Biotech f...rus, genomic data from the 1918 pandemic through t...nt H1N1 pandemic, today issued its latest biochemi... the lethality of the H1N1 ("Swine Flu") virus has...e virus,s current outbreak in the spring of 2009 t...
(Date:11/25/2009)..., MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma ...D to its Board of Directors. Dr. Moldt will replac...n the Company,s Board. The number of Board members...ery pleased to welcome Peter Moldt to the board an...nd guidance as Cytochroma continues to make progre...
(Date:11/25/2009)..., SAN DIEGO, Nov. 25 A...today that Barry D. Quart, Pharm.D., president and...r Jaffray 21st Annual Health Care Conference. , ,...y 21st Annual Health Care Conference,Date: Tu...rn Time,Location: The New York Palace Hotel, New ...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...AIN VIEW, Calif., March 12 Alexza,Pharmaceuticals...ll release,results for its fiscal year ended Decem...the close of the U.S. financial markets. The Compa...s the financial results and other,clinical develop...ay. A,replay of the call will be available for two...
...ded Agreement Accelerates Expected Timing of Final...le Powering of Interim and Final Results-, -Dendre...2008 at 11:00 AM ...daq: DNDN ) today announced that the U.S. Food an...ed Special Protocol Assessment (SPA) for the,Phase...
...nds PDE10 Collaboration with Amgen- -Com...ONTVALE, N.J., March 12 Memory,Pharmaceuticals Co...ealigned,its operations, reallocated its resources...its PDE10 collaboration with Amgen. The Company wi...o partnered programs, its,nicotinic alpha-7 recept...
Other Biology Technology:Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008 2Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008 3FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 2FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 3FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 2Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 3Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 5
(Date:11/30/2009)...y of Pittsburgh team overcame a major hurdle plagu... that could lead to more efficient catalysts used ...xic. The researchers reported Nov. 29 in Nature M...ure stability in metallic nanoparticles, the vaunt...bility to extreme heat. , Gtz Veser, an associat...
(Date:11/30/2009)...ournal of Experimental Biology are pleased to ann...e la Recherche Scientifique (CNRS) in the Universi...ear,s JEB Outstanding Paper Prize. ,The prize is...ent and is intended to encourage young scientists,...and adds that ,we truly appreciate when authors su...
(Date:11/30/2009)...er early bird registration rates and register onli...010 at http://www.iofwco-ecceo10.org/ , WHAT:...ational Osteoporosis Foundation (IOF) and the Euro...Osteoporosis and Osteoarthritis (ESCEO). More than...cted to attend. The exciting scientific programme ...
Breaking Biology News(10 mins):First metallic nanoparticles resistant to extreme heat 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Perrigo Company To Present at the Sidoti Emerging Growth Conference 6399 1How to execute dietary management in eating disorder patients 61699 1How to execute dietary management in eating disorder patients 61699 2TGen Drug Development establishes European footprint 10804 1TGen Drug Development establishes European footprint 10804 2
... identified a gene ?and the molecular function of ...ue to further understanding obesity and may point ..., The scientists found that the human protein know... activity may be an important pharmaceutical targe...conditions that range from obesity to the loss of ...
...a risk for gastrointestinal illness, most visitors...d prevent infection. In addition, some engage in b...on according to several studies being presented th...g Infectious Diseases. , Researchers from the CDC... of an outbreak of , E. coli O157:H7 associated ...
...ail of scents when they are attacked by certain pe...otton leaf worm. , Parasitic wasps use these plant...eir eggs on it, so that their offspring can feed o...es and the plant is relieved from its attacker. In... activated to attract the parasitic wasps. This ge...
Other Biology News:Rutgers researchers find fat gene 2Common practices at petting zoos put visitors at risk 2New possibilities to fight pests with biological means 2
Fingerprinting II Informatix, optional matrix types module from Bio-Rad
... Lines ,High Quality, Functionally-Validated, Ion ...for having a critical role in nerve and muscle fun..., CNS and the heart. Drugs that modulate ion chann...uch as neuropathic pain, cardiac arrhythmia, hyper...
...are derived from frozen embedded tissue blocks, wh...edures to ensure the highest quality. Tissues of e...tioned at a thickness of 7 microns and mounted on ...ter) in comparison to core sections made using Tis...
...ations or for use in an automated line. The StatMa...fold provides greater ease, speed, convenience, an...StatMatic II can be connected to a range of bottle...ne-handed operation -- in a matter of seconds.,T...
Biology Products: